There are 2137 resources available
1490P - Evaluation of circulating tumor cells in esophageal carcinoma patients who received chemotherapy or neoadjuvant chemotherapy
Presenter: Matsumoto Takuro
Session: E-Poster Display
Resources:
Abstract
1491P - Bespoke circulating tumor DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients
Presenter: Emma Ococks
Session: E-Poster Display
Resources:
Abstract
1492P - Investigation of DNA damage repair mutations and correlation with immunogenic biomarker in Chinese esophageal squamous cell carcinoma patients
Presenter: Wenyi Liu
Session: E-Poster Display
Resources:
Abstract
1493P - An integrated analysis of gene expression profile and chromosomal aberrations highlighted the oxidative stress role in anti-HER2 drug-resistant gastric cancer models
Presenter: Valentina Gambardella
Session: E-Poster Display
Resources:
Abstract
1494P - Updated safety data of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma - A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK
Presenter: Salah-Eddin Al-Batran
Session: E-Poster Display
Resources:
Abstract
1495P - FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – Final results from the phase II RAMIRIS Study of the AIO
Presenter: Peter Thuss-Patience
Session: E-Poster Display
Resources:
Abstract
1496TiP - Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18.2) in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma
Presenter: Florian Lordick
Session: E-Poster Display
Resources:
Abstract
1497TiP - REACTION – a phase Ib pilot study of nivolumab or nivolumab in combination with relatlimab after targeted radiation in patients with advanced esophagogastric cancer
Presenter: Vincent Lam
Session: E-Poster Display
Resources:
Abstract
1498TiP - A multi-center, randomized, open-label, phase III study of sintilimab + ramucirumab as 1st-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-106)
Presenter: Ruihua Xu
Session: E-Poster Display
Resources:
Abstract
1499TiP - FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for taxane-pretreated patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy – The phase II/III RAMIRIS study
Presenter: Salah-Eddin Al-Batran
Session: E-Poster Display
Resources:
Abstract